Ex-Alnara execs raise $15m series A for new company Allena
This article was originally published in Scrip
Executive Summary
Allena Pharmaceuticals, a new US biotech focused on developing novel non-systemic oral protein therapeutics, has raised $15 million in series A venture capital financing. Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures led the round.